BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 795 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 84.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,736 shares of the medical research company’s stock after purchasing an additional 795 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Bio-Rad Laboratories were worth $474,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Capital Advisors Ltd. LLC grew its holdings in shares of Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after buying an additional 62 shares during the last quarter. Sound Income Strategies LLC acquired a new position in Bio-Rad Laboratories during the 1st quarter valued at about $38,000. Gladius Capital Management LP boosted its stake in Bio-Rad Laboratories by 65.8% during the 4th quarter. Gladius Capital Management LP now owns 121 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 48 shares during the last quarter. Principal Securities Inc. bought a new stake in Bio-Rad Laboratories during the 4th quarter worth approximately $41,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Bio-Rad Laboratories in the first quarter worth approximately $51,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 369 shares of the business’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $281.91, for a total value of $104,024.79. Following the sale, the executive vice president now directly owns 6,573 shares in the company, valued at $1,852,994.43. The sale was disclosed in a filing with the SEC, which is accessible through this link. 17.06% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BIO has been the subject of several recent research reports. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 target price for the company. Citigroup boosted their price target on shares of Bio-Rad Laboratories from $300.00 to $350.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. UBS Group decreased their price objective on shares of Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $401.00 target price on shares of Bio-Rad Laboratories in a research report on Friday, August 16th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories has an average rating of “Hold” and an average price target of $358.20.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $334.50 on Wednesday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.59 and a fifty-two week high of $394.51. The company’s 50-day moving average is $310.05 and its 200 day moving average is $307.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28. The company has a market capitalization of $9.54 billion, a P/E ratio of -32.29 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.99. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The firm had revenue of $638.50 million during the quarter, compared to the consensus estimate of $645.79 million. During the same period in the prior year, the firm earned $3.00 EPS. The company’s revenue was down 6.3% compared to the same quarter last year. On average, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.31 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.